![]() |
市場調查報告書
商品編碼
1829225
2025年數位病理學全球市場報告Digital Pathology Global Market Report 2025 |
近年來,數位病理學市場快速擴張,從2024年的12.2億美元成長到2025年的14.2億美元,複合年成長率達15.7%。這段時期的成長可歸因於老年人口的快速成長、醫療事故的增加、癌症發生率的上升、慢性病的增加、醫療機構數量的增加、醫療支出的增加、公共醫療保險改革以及新冠疫情。
預計未來幾年數位病理學市場將快速成長,到2029年將達到27.9億美元,複合年成長率為18.4%。預測期內的成長歸因於政府支持、數位設備普及率的提高、癌症和慢性病發病率的上升、人口老化以及感染疾病的出現。預測期內的主要趨勢包括利用人工智慧提高自動化程度、專注於雲端技術以標準化和簡化數位病理學部署、採用數位成像和視訊串流技術、專注於開發新的技術解決方案、透過夥伴關係關係擴展產品系列以及投資研發活動。
數位病理學將數位成像引入病理學測試,使用載玻片掃描器硬體、軟體和相關服務將玻璃載玻片轉換為可以在電腦或行動電話螢幕上查看、管理和分析的高解析度數位影像。
數位病理學的關鍵產品包括掃描器、軟體、通訊系統和儲存系統。掃描儀利用顯微陣列技術創建病理切片的3D數位表示,以供檢視和自動影像分析。軟體有助於影像審查、分析和將數據傳輸為數位格式,以進行組織學成像分析。通訊系統有助於切片的收集、儲存、檢視以及各個組件之間的交互,以便與遠端同事進行即時遠端病理分析。儲存系統包括用於長期樣本分析和預測分析的數位檔案。病理學分為人類病理學和獸醫病理學。數位病理學的應用範圍廣泛,包括製藥和生物技術公司、醫院、參考實驗室以及學術和研究機構。應用範圍從藥物研發和疾病診斷到遠距會診、培訓和教育。
2025年春季,美國關稅突然上調及其引發的貿易摩擦對醫療設備產業產生了重大影響,尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制漲價,製造商面臨利潤壓力。監管挑戰進一步加劇了形勢,因為由於關稅而更換供應商通常需要醫療設備重新認證,導致市場准入延遲。為此,企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快尋找更具成本效益的材料來降低風險。
本研究報告是商業研究公司 (The Business Research Company) 新報告系列的一部分,該系列提供數位病理學市場統計數據,例如全球數位病理學市場規模、各地區市場佔有率、競爭對手的市場佔有率、詳細的數位病理學細分市場、市場趨勢和商業機會,以及您在數位病理學行業取得成功所需的數據。本數位病理學市場研究報告對該行業的現狀和未來趨勢進行了詳細分析,為您提供所需的一切資訊的完整觀點。
未來五年的預測成長率為18.4%,較我們先前對該市場的預測略有下降0.3%。下降主要源自於美國與其他國家之間關稅的影響。這種影響可能會直接影響美國,導致來自瑞典和新加坡等主要地區的全切片成像掃描儀和雲端基礎影像分析平台的供應鏈中斷,這可能導致癌症診斷延遲和實驗室數位轉型成本增加。由於互惠關稅以及貿易緊張局勢和限制加劇對全球經濟和貿易的負面影響,這種影響可能會更加廣泛。
癌症發生率的上升是數位病理學市場擴張的主要原因。隨著人口老化,由於細胞變化和長期暴露於各種風險因素,罹患癌症的可能性增加。此外,吸煙、不良飲食、缺乏運動和過量飲酒等生活方式選擇進一步增加了癌症的風險。數位病理學能夠快速診斷和治療癌症,使其成為管理這一日益嚴重的健康問題的重要工具。例如,2024 年 1 月,美國致力於癌症宣傳的美國癌症協會報告稱,癌症患者數量從 2023 年的 1,958,310 人增加到 2024 年的 2,001,140 人,增加了 2.19%。因此,預計未來癌症患者數量的增加將推動數位病理學市場的成長。
數位病理學市場預計將受益於感染疾病的出現和新病原體的傳播。 SARS、茲卡病毒、伊波拉出血熱和 COVID-19 等疾病的爆發導致全球感染疾病增加,增加了全球疾病負擔。數位病理學有助於對疑似感染疾病的病理診斷進行即時諮詢,使病理學家、實驗室技術人員和其他專家能夠有效協作。通用感染疾病是起源於動物並進化以感染人類的疾病。它們佔已知人類病原體的約 60% 和新興人類病原體的 75%。氣候變遷預計將透過影響微生物及其媒介的地理範圍來改變感染疾病的流行病學。隨著微生物適應更高的溫度,能夠突破人類防禦的耐熱微生物將被選擇,這可能導致新感染疾病的出現和現有疾病流行病學的變化。這種動態場景正在推動對數位病理學的需求並支持市場成長。
過去,訓練有素的病理學家短缺曾為數位病理學市場帶來挑戰。病理學家在進行疾病診斷所必需的實驗室檢測(包括醫學樣本的檢查和解讀)方面發揮著至關重要的作用。亞太和非洲國家的病理學家短缺正在影響醫學樣本的及時檢測。例如,2022年2月, 《法醫學雜誌》的一篇報告指出,有217具屍體積壓等待國家法醫學病理學家的檢驗,並預測這一數字將在兩週內上升到300具。此外,還有200多具屍體等待屍檢,凸顯了病理學家資源的緊張。
人工智慧 (AI) 是數位病理學市場中一個日益突出的趨勢。醫療保健公司正在利用 AI 來增強各種業務流程的自動化。使用影像分類的 AI 演算法有助於檢測與人類疾病(例如癌細胞)以及農業問題(例如葉片變色和腐爛)相關的特徵。 2022 年 1 月,美國病理實驗室 Inform Diagnostics 在其實驗室中引入了 Paige FullFocus 數位病理學檢視器。這項新技術的引入使 Inform Diagnostics 的病理學家能夠利用 AI 工具、簡化物流並加快結果獲取速度。
2022年3月,總部位於英國的綜合實驗室服務和產品供應商SourceBio International PLC成功以1,850萬英鎊(1,976萬美元)收購了LDPath Ltd。該公司計劃利用過去兩年COVID-19 PCR檢測服務產生的資金,策略性地回購股份。此次收購將增強SourceBio International作為英國NHS信託機構和私人醫療保健提供者領先的細胞病理學檢測外包合作夥伴的地位。擴大後的集團旨在推動NHS和私人客戶採用數位病理學服務。 LDPath是一家總部位於英國的專業數位病理學檢測服務提供者。
數位病理學市場的主要企業包括丹納赫集團、霍夫曼羅氏有限公司、荷蘭皇家飛利浦公司、濱松光子學株式會社、3DHISTECH 有限公司、奧林巴斯公司、尼康公司、Visiopharm A/S、Indica Labs Inc、Sectra AB、Grundium、徠卡生物系統成像公司、阿波羅公司Doc、Ventana Medical Systems、Huron Digital Pathology、Synevo、Paige.ai、Morphle、Akoya、Aperio Digital Pathology、Smart in Media、MaRS、珀金埃爾默、Definiens AG、Digipath、CAE、Medical-X、C3+ Holter Monitor、BIOEGYPT 和 Pulse。
2024年,數位病理學市場最大的地區是北美。亞太地區是數位病理學市場的第二大地區。數位病理學市場報告涵蓋亞太地區、西歐、中歐和東歐、北美、南美以及中東和非洲。
數位病理學市場報告涵蓋的國家有澳洲、巴西、中國、法國、德國、印度、印尼、日本、俄羅斯、韓國、英國、美國、義大利、西班牙和加拿大。
數位病理學市場包括切片掃描儀、軟體和試劑的銷售。該市場的價值指的是“出廠價”,即商品製造商或創造者向其他營業單位(包括下游製造商、批發商、經銷商和零售商)或直接向最終客戶銷售的商品價值。該市場中的商品價值還包括商品創造者銷售的任何相關服務。
Digital pathology involves utilizing digital imaging for pathology procedures, converting glass slides into high-resolution digital images using slide scanner hardware, software, and related services. These digital images are viewable, manageable, and analyzable on computer or mobile screens.
Key products in digital pathology include scanners, software, communication systems, and storage systems. Scanners utilize microscopic array technology to create three-dimensional digital representations of pathology slides for viewing and automated image analysis. Software aids in transferring data to digital formats for image review, analysis, and tissue image analysis. Communication systems facilitate interaction between various components for slide acquisition, storage, viewing, and real-time telepathology with remote colleagues. Storage systems involve digital archives for long-term sample analysis and predictive analytics. Pathology branches into human pathology and veterinary pathology. Digital pathology finds application across pharmaceutical & biotechnology companies, hospitals, reference laboratories, academic & research institutes. Its uses encompass drug discovery, disease diagnosis, teleconsultation, and training & education purposes.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.
The digital pathology market research report is one of a series of new reports from The Business Research Company that provides digital pathology market statistics, including digital pathology industry global market size, regional shares, competitors with a digital pathology market share, detailed digital pathology market segments, market trends and opportunities, and any further data you may need to thrive in the digital pathology industry. This digital pathology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The digital pathology market size has grown rapidly in recent years. It will grow from $1.22 billion in 2024 to $1.42 billion in 2025 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to rapid growth in the elderly population, increase in medical errors, increase in cancer prevalence, increase in chronic diseases, growth in the number of healthcare facilities, increased healthcare expenditure, public health insurance reforms, and the COVID-19 pandemic.
The digital pathology market size is expected to see rapid growth in the next few years. It will grow to $2.79 billion in 2029 at a compound annual growth rate (CAGR) of 18.4%. The growth in the forecast period can be attributed to government support, increasing adoption of digital devices, increasing prevalence of cancer and chronic diseases, aging population, and the emergence of infectious diseases. Major trends in the forecast period include leveraging artificial intelligence to improve automation, focusing on cloud technology to standardize and simplify digital pathology deployments, adopting digital imaging and video streaming technology, focusing on developing new technological solutions, focusing on partnerships to expand product portfolio and investing in research and development (R&D) activities.
The forecast of 18.4% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for whole-slide imaging scanners and cloud-based image analysis platforms, sourced from key regions such as Sweden and Singapore, which could lead to delayed cancer diagnoses and increased laboratory digital transformation costs.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising incidence of cancer is significantly contributing to the expansion of the digital pathology market. As populations age, the likelihood of developing cancer increases due to cellular changes and prolonged exposure to various risk factors. Additionally, lifestyle choices such as smoking, poor diet, insufficient physical activity, and excessive alcohol consumption further elevate cancer risk. Digital pathology facilitates quicker diagnosis and treatment of cancer, making it a vital tool in managing this growing health concern. For example, in January 2024, the American Cancer Society, a US-based nonprofit organization focused on cancer advocacy, reported that the number of cancer cases rose to 2,001,140 in 2024, up from 1,958,310 in 2023, marking an increase of 2.19%. Consequently, the rising prevalence of cancer is expected to drive the growth of the digital pathology market in the future.
The digital pathology market is anticipated to receive support from the emergence of infectious diseases and novel pathogenic infestations. Outbreaks of diseases such as SARS, Zika virus, Ebola, and COVID-19 have led to increased infections worldwide, elevating the global disease burden. Digital pathology facilitates real-time consultation for pathologic diagnosis in suspected cases of infectious diseases, enabling professionals such as pathologists and laboratorians to collaborate effectively. Zoonotic infectious agents, which are diseases that originate in animals and evolve to infect humans, account for about 60% of known human pathogens and up to 75% of emerging human pathogens. Climate change is expected to alter the epidemiology of infectious diseases by influencing the geographic ranges of microbes and vectors. As microbes adapt to higher temperatures, concerns arise about the selection of heat-tolerant microbes that can overcome human defenses, leading to new infectious diseases and altering the epidemiology of existing diseases. This dynamic scenario fuels the demand for digital pathology, supporting market growth.
The shortage of trained pathologists posed a challenge to the digital pathology market in the historical period. Pathologists play a crucial role in conducting essential laboratory tests for disease diagnosis, involving the examination and interpretation of medical laboratory samples. The Asia-Pacific region and several African countries face a scarcity of pathologists, impacting the timely examination of medical samples. For instance, in February 2022, a forensic magazine report highlighted a backlog of 217 bodies awaiting examination by state forensic pathologists, with projections of the figure rising to 300 in less than two weeks. Additionally, more than 200 bodies were awaiting autopsies, emphasizing the strain on pathologist resources.
Artificial intelligence (AI) stands out as a prominent trend gaining traction in the digital pathology market. Healthcare companies leverage AI to enhance the automation of various operational processes. AI algorithms, utilizing image classification, contribute to the detection of features associated with human diseases, such as cancer cells, and agricultural issues such as leaf coloring and decay. In January 2022, Inform Diagnostics, a US-based pathology lab, introduced the Paige FullFocus digital pathology viewer in its laboratories. This adoption of new technology empowers pathologists at Inform Diagnostics to leverage AI tools, streamline logistics, and achieve faster turnaround times for results.
In March 2022, SourceBio International PLC, a UK-based provider of integrated laboratory services and products, successfully completed the acquisition of LDPath Ltd for an initial amount of £18.5 million ($19.76 million). The company is strategically planning a share buyback, utilizing the funds generated from its Covid PCR testing services over the preceding two years. This acquisition enhances SourceBio International's position, aiming to become the leading outsourced partner for delivering cellular pathology testing to NHS trusts and private healthcare providers in the UK. The expanded group has set its sights on converting both NHS and private clients to embrace digital pathology services. LDPath Ltd is a UK-based provider specializing in digital pathology testing services.
Major companies operating in the digital pathology market include Danaher Corporation, Hoffmann-La Roche Ltd, Koninklijke Philips N.V, Hamamatsu Photonics K.K, 3DHISTECH Ltd, Olympus Corporation, Nikon Corporation, Visiopharm A/S, Indica Labs Inc, Sectra AB, Grundium, Leica Biosystems, Apollo Enterprise Imaging Corp, Inspirata Inc, PathAI, Aiforia Technologies, Proscia, Ibex Medical Analytics, Better Doc, Ventana Medical Systems, Huron Digital Pathology, Synevo, Paige.ai, Morphle, Akoya, Aperio Digital Pathology, Smart in Media, MaRS, Perkin Elmer, Definiens AG, Digipath, CAE, Medical-X, C3? Holter Monitor, BIOEGYPT, Pulse
North America was the largest region in the digital pathology market in 2024. Asia-Pacific was the second-largest region in the digital pathology market. The regions covered in the digital pathology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the digital pathology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The digital pathology market consists of the sales of slide scanners, software, and reagents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Digital Pathology Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on digital pathology market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for digital pathology ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The digital pathology market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.